ZUP1 and cancer: With the growing understanding of the molecular biology of the UPS, proteasome and DUB inhibition have proven to be attractive strategies for cancer therapy.27, 32 Importantly, in contrast to 20 S proteasome inhibitor, most of reported DUB inhibitors can specifically target one or several DUBs by which more specific and less toxic anticancer agents may be generated.